Catheter Precision, Inc. (VTAK): Unregistered Sales of Equity Securities
Catheter Precision, Inc. (VTAK) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. EX-3.1 2 ex_988166.htm EXHIBIT 3.1 SERIES C-3 DESIGNATION ex_988166.htm Exhibit 3.1 CATHETER PRECISION, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES C-3 CONVERTIBLE PREFERRED STOCK The undersigned, Philip Anderson, does hereby certify that: 1.
How this was made
The 30-second read
Why it matters
For VTAK, the key tradable question is how much equity was sold, at what effective price, and how conversion into common stock could create near-term dilution or selling pressure.
Market read
This is a primary SEC disclosure of unregistered equity sales, which can change dilution expectations and trigger short-term repricing.
What to watch
Traders should check the missing parts of the 8-K for the actual number of shares sold, purchasers, proceeds, and whether registration rights are already effective or delayed, since those details drive dilution and overhang.
Background
The SEC 8-K Item 3.02 is used to report unregistered equity security sales, often connected to preferred stock issuances with conversion features and potential registration rights.
Ticker impact
Catheter Precision filed an 8-K for Item 3.02, disclosing unregistered sales of equity securities tied to its Series C-3 preferred stock terms.
Bias toward downside or volatility until investors assess dilution size, conversion terms, and any registration rights timeline.
Item 3.02 specifically flags unregistered equity sales, and the exhibit describes Series C-3 preferred stock with conversion mechanics, both of which typically matter for dilution and liquidity over the next sessions to weeks.
Market effects
Adds to the broader small-cap biotech/medical-device financing backdrop where unregistered preferred issuances can pressure peers via read-across on dilution practices.
Primarily US micro/small-cap sentiment; limited direct regional spillover beyond similar issuers.
Low global relevance; mostly affects domestic investors tracking US-listed microcaps and SEC filing-driven flows.
Counterpoint
Unregistered sales can be routine under exemptions and may not imply large incremental dilution if proceeds are modest or conversion is constrained by beneficial ownership limits.
Key entities
- issuerCatheter Precision, Inc.
US-listed company filing 8-K Item 3.02 for unregistered sales of equity securities.
- securitySeries C-3 Convertible Preferred Stock
Preferred stock series described in the exhibit, including conversion-related definitions and terms.
- executivePhilip Anderson
CFO signing the certificate of designation for Series C-3 preferred stock.
